FDA staff report says data shows Pfizer’s Covid treatment Paxlovid is effective in high-risk adults

U.S. Food and Drug Administration staff said Pfizer’s clinical trial results on its Covid antiviral pill Paxlovid support the drug’s use in adults at high risk of progressing to severe disease.
The FDA staff made the conclusion in briefing documents ahead of a meeting on Thursday, where external advisors will discuss the full approval of Paxlovid for the treatment of mild to moderate Covid in high-risk adults.